Organogenesis Holdings Inc. (NASDAQ:ORGO) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 5:00 PM Eastern Time.
The conference call will be webcast live on Internet at organogenesis.com
Earnings Expectation
Organogenesis Holdings Inc. is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ORGO is expected to report 3Q20 loss of $ 0.08 per share from revenue of $ 71.96 million.
For the full year, analysts anticipate top line of $ 275.12 million, while looking forward to loss of $ 0.39 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 273.00 million ~ $ 277.00 million
Click Here For More Historical Outlooks Of Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The companys advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds.
